Chromatographic Characterization of Biologics
Characterizing biologics through chromatographic analysis.
Protein biologics now represent a significant share of pharmaceutical sales and future growth potential, particularly in an era of increasing patent expirations and generic versions of small-molecule drugs. Their specificity has been their key to success, as their cell-specific modality and relative lack of compound-specific toxicity have provided safer and more effective means to treat several chronic diseases. Sufferers of rheumatoid arthritis and other autoimmune diseases, cancer and diabetes have been among the benefactors of the protein biologics developed to date. The most common class of proteins used as pharmaceuticals has been monoclonal antibodies (mAbs), representing over 30% of the global biologic drug market, according to a recent market report, and there are more than 20 FDA approved mAb drugs already on the market.
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
